Emmaus Life Sciences, Inc. · OTC:EMMA

Emmaus Life Sciences — MYnd Analytics — IPO Roadshow (July 2017)

25 slides from Emmaus Life Sciences's IPO roadshow presentation, Jul 3, 2017

  1. Slide 1: Predictive Medicine for Mental Health

    PREDICTIVE MEDICINE FOR MENTAL HEALTH Investor Presentation July 2017

  2. Slide 2: Forward-looking statements

    This presentation contains “forward - looking statements” pursuant to the safe - harbor provisions of the Private Securities Litigation Reform Act of 1995 that include information relating to future events, future financial performance, strategies, expectations, competitive environment, regulation a

  3. Slide 3: Public Offering Summary

    Issuer: MYnd Analytics, Inc. (OTCQB: MYAN) Proposed Exchange / Ticker: NASDAQ Capital Market / MYND and MYND.W Securities Offered: • $9,000,000 of common stock • 100% warrant coverage Over - allotment: 15% (100% primary shares) Common Stock Outstanding Before the Offering: 2,539,061 shares Closing P

  4. Slide 4: MYnd Analytics business and technology platform

    • MYnd Analytics is a predictive analytics company that develops decision support tools to guide personalized treatment of behavioral disorders, including depression, anxiety, bipolar disorder, and post - traumatic stress disorder (PTSD) Our Business • MYnd’s Psychiatric Electroencephalography Evalu

  5. Slide 5: Board of Directors and management

    Board of Directors Investor Presentation 5 George C. Carpenter – President & CEO • Over 25 years of experience in healthcare technology and business development • MBA in Finance from the University of Chicago, BA from Dartmouth College Brian MacDonald – Chief Technology Officer • Responsible for mac

  6. Slide 6: Mental Health - Incidence & Cost

    • Globally, an estimated 300 million people suffer from depression and 60 million have Bipolar affective disorder (1) • Anxiety disorders are the most common mental illness in the U.S. affecting 40 million adults (2) • It is estimated that 129 million children globally have Attention - deficit/hyper

  7. Slide 7: MHSUD U.S. Spending

    • Mental disorders, including substance abuse, have the highest estimated annual health spending in the U.S. • In 2013, healthcare spending on mental disorders reached $201 Billion (1) MENTAL HEALTH & SUBSTANCE USE DISORDERS (MHSUD) U.S. SPENDING Investor Presentation 7 Source: “Mental Disorders Top

  8. Slide 8: Impact of MHSUD on Common High Cost Medical Conditions

    Source: Melek S., Norris D., Paulus J.: Economic Impact of Integrated Medical - Behavioral Healthcare: Implications for Psychiatry. Prepared for APA; 2014, pp.1 - 39. Investor Presentation 8 Population % with Behavioral Health (BH) Diagnosis Per - member per - month (PMPM) cost without BH Diagnosis

  9. Slide 9: Mental Health Medications Are Second Most Prescribed Therapeutic Class

    Dispensed Prescriptions (in millions) 2011 2012 2013 2014 2015 US Market 4,014 4,155 4,236 4,325 4,368 Antihypertensives 649 691 701 705 706 Mental Health 495 511 523 537 547 Pain 472 484 481 483 470 Source: IMS Health, National Prescription Audit, Dec. 2015. MENTAL HEALTH MEDICATIONS ARE SECOND MOS

  10. Slide 10: Trial and Error Pharmacotherapy

    TRIAL AND ERROR PHARMACOTHERAPY Investor Presentation 10 “Current medications are not sufficient for most patients... We still do not know who will respond to a specific treatment. Even for the fraction of patients who ultimately respond, clinicians often must resort to trial and error before findin

  11. Slide 11: Mental Health Market: Significant Unmet Need

    MENTAL HEALTH MARKET: SIGNIFICANT UNMET NEED Of all people living with mental disorders • 12% are treated by a psychiatrist • 20% are treated by a mental health physician • 40 % are treated by a healthcare professional • 60% get no formal treatment Investor Presentation 11

  12. Slide 12: Proprietary Outcomes Registry

    PROPRIETARY OUTCOMES REGISTRY Investor Presentation 12 MYnd Clinical Registry 10,200+ Unique Patients 38,000+ Total Outcomes • Strong intellectual property protection with 22 issued patents and 1 patent pending • Technical know - how and proprietary algorithm developed and owned by MYnd • First move

  13. Slide 13: Growing Evidence

    “ EEG recording and analysis is currently experiencing a renaissance in interest and in both range and depth of applications, particularly in the search for endo - phenotypes and biomarkers for etiologic factors, individual diagnosis, risk for disorder, and treatment response.” Use of EEG Biomarkers

  14. Slide 14: Can Technology Reduce Trial and Error?

    “Technology CAN make a difference for mental health care. Digital phenotyping, like what PEER does with EEG, or with wearables or smartphone technology, can capture precise, continuous, objective measures of behavior… that’s a game changer for Psychiatry, and actually for the whole field of mental h

  15. Slide 15: Current Technologies Used to Guide Treatment

    Category Clinical Practice Application Examples Functional imaging Identifies brain regions associated with cognitive impairments, hyper/hypoactivation; no regulatory clearance for MH Amen Clinics Pharmacogenomic (PGx) testing CLIA Lab Developed Tests show activity of enzymes which impact drug metab

  16. Slide 16: The Process

    Patient and Doctor agree PEER is needed (can be a Psychiatrist or Primary Care Physician) An EEG test measures the patient’s unique brain patterns. The test is non - invasive , inexpensive, widely available and has a reimbursement code Patient’s EEG is compared to PEER database, which improves with

  17. Slide 17: Interim Findings from the 4th Clinical Trial: Walter Reed PEER Trial

    • Patients had a median of 5 visits compared to 2 visits for patients whose physicians used PEER as compared to those that did not follow PEER 144% 75% 75% 139% D e pr e s s ion Suicidality Global Improvement P T S P e r ce n t (1) VA/DOD Clinical Practice Guideline for Management of Major Depressiv

  18. Slide 18: Commercialization Strategy

    COMMERCIALIZATION STRATEGY Managed Care Payers and health systems seeking to improve clinical outcomes and lower health care costs VA/Military Where suicide rates are high and need for innovative and effective mental health care is high Provider Direct Multi - practitioner provider groups seeking to

  19. Slide 19: Milestones Over Next Months

    MILESTONES OVER NEXT 12 MONTHS Investor Presentation 19 1 Establish paid pilot program(s) with managed care companies and health systems seeking to improve clinical outcomes and lower health care costs 2 Show pharmacoeconomic benefits when providers use the PEER report on - line tool 3 Penetrate VA

  20. Slide 20: Additional Service Lines

    ADDITIONAL SERVICE LINES Problem Looming crisis in access to care • Psychiatrist shortage • Waiting lists are high • 70% of mental health is treated by PCPs • Waste due to low attendance and adherence to treatment (avg = 2 visits) Impact: • Over half of patients never seek treatment • Treatments the

  21. Slide 21: Digital Health Care: Investments

    MYND is in one of the hottest areas of AI/digital health care DIGITAL HEALTH CARE: INVESTMENTS Investor Presentation 21

  22. Slide 22: Financial Summary and Capitalization

    Common shares 2,528,061 46.7% Options 348,095 6.4% Warrant s (2) 2,534,956 46.9% Fully - diluted shares outstanding 5,411,112 10 0 .0% Investor Presentation 22 (U.S. dollars) As of March 31, 2017 Cash and cash equivalents $1,754,400 Total assets 2,430,100 Total liabilities 1,903,300 Shareholders’ eq

  23. Slide 23: Digital Health Care acquisitions

    Source: RockHealth, 2016 https://rockhealth.com/reports/digital - health - exits - 2016 - ytd - 112 - digital - health - acquisitions - and - two - ipos/. Investor Presentation 23 Target Acquired By Acquisition Amount Change Healthcare McKesson $3.0B Truven Analytics IBM $2.6B eResearchTechnology No

  24. Slide 24: Investment highlights

    • CLINICAL NEED: Mental disorders are the greatest cause of disability and number one reason why people miss work • MARKET OPPORTUNITY : $21 billion are spent annually on mental health medications making them the second most commonly prescribed therapeutic class behind anti - hypertensives even thou

  25. Slide 25: Contact

    Robin L. Smith, MD, MBA, Chairman of the Board tel: 917 - 691 - 7409 email: robin@robinlsmith.com George C. Carpenter IV , President and Chief Executive Officer tel: 949 - 697 - 2161 email: gcarpenter@myndanalytics.com Don D’Ambrosio Chief Financial Officer tel: 949 - 420 - 4402 email: ddambrosio@my

MYnd Analytics — IPO Roadshow (July 2017) on 6ix